Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.

Kristian ReichA PinterJ P LacourC FerrandizG MicaliL E FrenchM LomagaY DutroncC HennegesS WilhelmS HartzCarle F Paulnull null

Published in: The British journal of dermatology (2017)

The superior efficacy of IXE demonstrated at week 12 persisted up to week 24. The safety profiles were consistent with those previously reported for both treatments.

Keyphrases

phase iii
placebo controlled
double blind
open label
clinical trial
phase ii
early onset
randomized controlled trial
drug induced